Sulopenem Explained
Sulopenem (CP-70,429) is an antibiotic derivative from the carbapenem family, which unlike most related drugs is orally active. It was developed in Japan in the 1990s but has never been approved for medical use, however it has reached Phase III clinical trials on several occasions and continues to be the subject of ongoing research into potential applications, especially in the treatment of multiple drug resistant urinary tract infections.[1] [2] [3] [4] [5]
See also
Notes and References
- Minamimura M, Taniyama Y, Inoue E, Mitsuhashi S . In vitro antibacterial activity and beta-lactamase stability of CP-70,429 a new penem antibiotic . Antimicrobial Agents and Chemotherapy . 37 . 7 . 1547–1551 . July 1993 . 8363389 . 10.1128/AAC.37.7.1547 . 188011 .
- Hamilton-Miller JM . Chemical and microbiologic aspects of penems, a distinct class of beta-lactams: focus on faropenem . Pharmacotherapy . 23 . 11 . 1497–1507 . November 2003 . 14620395 . 10.1592/phco.23.14.1497.31937 . 43705118 .
- Ednie LM, Appelbaum PC . Antianaerobic activity of sulopenem compared to six other agents . Antimicrobial Agents and Chemotherapy . 53 . 5 . 2163–2170 . May 2009 . 19223615 . 10.1128/AAC.01557-08 . 2681565 .
- Bader MS, Loeb M, Leto D, Brooks AA . Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents . Postgraduate Medicine . 132 . 3 . 234–250 . April 2020 . 31608743 . 10.1080/00325481.2019.1680052 . 204545734 .
- Veeraraghavan B, Bakthavatchalam YD, Sahni RD . Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections . Infectious Diseases and Therapy . 10 . 4 . 1815–1835 . December 2021 . 34357517 . 10.1007/s40121-021-00509-4 . 8572892 .